Infliximab is a chimeric monoclonal antibody that functions by binding to and inhibiting tumor necrosis factor-alpha (TNF-α), a key cytokine involved in systemic inflammation. Clinically, this medication… Read more
Infliximab is a chimeric monoclonal antibody that functions by binding to and inhibiting tumor necrosis factor-alpha (TNF-α), a key cytokine involved in systemic inflammation. Clinically, this medication is indicated for managing various autoimmune and inflammatory conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and psoriasis. Analytical laboratories require high-quality reference standards for Infliximab API, along with associated impurities and stable isotope-labelled compounds, to ensure robust method validation and precise quality control. These materials are essential for accurate impurity profiling and quantitation within complex biological matrices, facilitating rigorous regulatory compliance. By utilizing reliable reference materials and isotopically labelled internal standards, researchers can effectively monitor degradation pathways and verify the structural integrity of the therapeutic agent throughout its lifecycle, ensuring the consistent safety and efficacy of the biological product in clinical settings.